Today's trade is in a mental health biotech company focused on developing psychedelic-assisted therapies — primarily a synthetic form of psilocybin called COMP360 — for difficult-to-treat psychiatric conditions.
I believe in this company's mission. I believe in the power of psilocybin to help people suffering from addictions to alcohol. I believe in its ability to treat people suffering from PTSD and trauma. And I believe in its uses as a tool in therapeutic settings to help people work through many of life's challenges.
I believe in it because it has helped me.
Does this make me biased? Maybe.
But the chart backs up my feeling that we're on the verge of some serious breakthroughs.
You need to have a subscription to access this content in full.
Log in or subscribe today to unlock new features and receive Member Benefits.
